hACE2 Citations (40)

Originally described in: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M Nature. 2003 Nov 27. 426(6965):450-4. PubMed Journal

---

Articles Citing hACE2

Articles
Upregulation of Angiotensin (1-7)-Mediated Signaling Preserves Endothelial Function Through Reducing Oxidative Stress in Diabetes. Zhang Y, Liu J, Luo JY, Tian XY, Cheang WS, Xu J, Lau CW, Wang L, Wong WT, Wong CM, Lan HY, Yao X, Raizada MK, Huang Y. Antioxid Redox Signal. 2015 May 14. PubMed
A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Dieterle ME, Haslwanter D, Bortz RH 3rd, Wirchnianski AS, Lasso G, Vergnolle O, Abbasi SA, Fels JM, Laudermilch E, Florez C, Mengotto A, Kimmel D, Malonis RJ, Georgiev G, Quiroz J, Barnhill J, Pirofski LA, Daily JP, Dye JM, Lai JR, Herbert AS, Chandran K, Jangra RK. bioRxiv. 2020 May 20. doi: 10.1101/2020.05.20.105247. PubMed
The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types. Daniloski Z, Guo X, Sanjana NE. bioRxiv. 2020 Jun 15. doi: 10.1101/2020.06.14.151357. PubMed
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, Narayanan A, Majowicz SA, Kwong EM, McVicar RN, Thacker BE, Glass CA, Yang Z, Torres JL, Golden GJ, Bartels PL, Porell RN, Garretson AF, Laubach L, Feldman J, Yin X, Pu Y, Hauser BM, Caradonna TM, Kellman BP, Martino C, Gordts PLSM, Chanda SK, Schmidt AG, Godula K, Leibel SL, Jose J, Corbett KD, Ward AB, Carlin AF, Esko JD. Cell. 2020 Nov 12;183(4):1043-1057.e15. doi: 10.1016/j.cell.2020.09.033. Epub 2020 Sep 14. PubMed
Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells. Schweitzer KS, Crue T, Nall JM, Foster D, Sajuthi S, Correll KA, Nakamura M, Everman J, Downey GP, Seibold MA, Bridges JP, Serban KA, Chu HW, Petrache I. Eur Respir J. 2021 Jan 8. pii: 13993003.03988-2020. doi: 10.1183/13993003.03988-2020. PubMed
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Tan TK, Rijal P, Rahikainen R, Keeble AH, Schimanski L, Hussain S, Harvey R, Hayes JWP, Edwards JC, McLean RK, Martini V, Pedrera M, Thakur N, Conceicao C, Dietrich I, Shelton H, Ludi A, Wilsden G, Browning C, Zagrajek AK, Bialy D, Bhat S, Stevenson-Leggett P, Hollinghurst P, Tully M, Moffat K, Chiu C, Waters R, Gray A, Azhar M, Mioulet V, Newman J, Asfor AS, Burman A, Crossley S, Hammond JA, Tchilian E, Charleston B, Bailey D, Tuthill TJ, Graham SP, Duyvesteyn HME, Malinauskas T, Huo J, Tree JA, Buttigieg KR, Owens RJ, Carroll MW, Daniels RS, McCauley JW, Stuart DI, Huang KA, Howarth M, Townsend AR. Nat Commun. 2021 Jan 22;12(1):542. doi: 10.1038/s41467-020-20654-7. PubMed
A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering. Zhu J, Ananthaswamy N, Jain S, Batra H, Tang WC, Lewry DA, Richards ML, David SA, Kilgore PB, Sha J, Drelich A, Tseng CK, Chopra AK, Rao VB. bioRxiv. 2021 Jan 20. doi: 10.1101/2021.01.19.427310. PubMed
A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S, Pham TD, Pak JE, Chiu W, Kim PS. ACS Cent Sci. 2021 Jan 27;7(1):183-199. doi: 10.1021/acscentsci.0c01405. Epub 2021 Jan 5. PubMed
The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. Daniloski Z, Jordan TX, Ilmain JK, Guo X, Bhabha G, tenOever BR, Sanjana NE. Elife. 2021 Feb 11;10. pii: 65365. doi: 10.7554/eLife.65365. PubMed Associated Plasmids pcDNA3.1-SARS2-Spike-D614G
Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Baggen J, Persoons L, Vanstreels E, Jansen S, Van Looveren D, Boeckx B, Geudens V, De Man J, Jochmans D, Wauters J, Wauters E, Vanaudenaerde BM, Lambrechts D, Neyts J, Dallmeier K, Thibaut HJ, Jacquemyn M, Maes P, Daelemans D. Nat Genet. 2021 Apr;53(4):435-444. doi: 10.1038/s41588-021-00805-2. Epub 2021 Mar 8. PubMed
Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units. Janaka SK, Hartman W, Mou H, Farzan M, Stramer SL, Goodhue E, Weiss J, Evans D, Connor JP. medRxiv. 2021 Mar 1. doi: 10.1101/2021.02.25.21252463. PubMed
Angiotensin converting enzyme 2 is a novel target of the gamma-secretase complex. Bartolome A, Liang J, Wang P, Ho DD, Pajvani UB. Sci Rep. 2021 May 7;11(1):9803. doi: 10.1038/s41598-021-89379-x. PubMed Associated Plasmids pcDNA3.1-ACE2-GFP pCSDest-HA-TMPRSS2 pCSDest-MYC-TMPRSS2
SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Gutmann C, Takov K, Burnap SA, Singh B, Ali H, Theofilatos K, Reed E, Hasman M, Nabeebaccus A, Fish M, McPhail MJ, O'Gallagher K, Schmidt LE, Cassel C, Rienks M, Yin X, Auzinger G, Napoli S, Mujib SF, Trovato F, Sanderson B, Merrick B, Niazi U, Saqi M, Dimitrakopoulou K, Fernandez-Leiro R, Braun S, Kronstein-Wiedemann R, Doores KJ, Edgeworth JD, Shah AM, Bornstein SR, Tonn T, Hayday AC, Giacca M, Shankar-Hari M, Mayr M. Nat Commun. 2021 Jun 7;12(1):3406. doi: 10.1038/s41467-021-23494-1. PubMed
Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2. Zhao M, Su PY, Castro DA, Tripler TN, Hu Y, Cook M, Ko AI, Farhadian SF, Israelow B, Dela Cruz CS, Xiong Y, Sutton RE. PLoS Pathog. 2021 Jun 24;17(6):e1009683. doi: 10.1371/journal.ppat.1009683. eCollection 2021 Jun. PubMed
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. Tea F, Ospina Stella A, Aggarwal A, Ross Darley D, Pilli D, Vitale D, Merheb V, Lee FXZ, Cunningham P, Walker GJ, Fichter C, Brown DA, Rawlinson WD, Isaacs SR, Mathivanan V, Hoffmann M, Pohlman S, Mazigi O, Christ D, Dwyer DE, Rockett RJ, Sintchenko V, Hoad VC, Irving DO, Dore GJ, Gosbell IB, Kelleher AD, Matthews GV, Brilot F, Turville SG. PLoS Med. 2021 Jul 6;18(7):e1003656. doi: 10.1371/journal.pmed.1003656. eCollection 2021 Jul. PubMed
Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection. Sohn SY, Hearing J, Mugavero J, Kirillov V, Gorbunova E, Helminiak L, Mishra S, Mackow E, Hearing P, Reich NC, Kim HK. mBio. 2021 Dec 21;12(6):e0275621. doi: 10.1128/mBio.02756-21. Epub 2021 Nov 2. PubMed
Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. Ashhurst AS, Tang AH, Fajtova P, Yoon MC, Aggarwal A, Bedding MJ, Stoye A, Beretta L, Pwee D, Drelich A, Skinner D, Li L, Meek TD, McKerrow JH, Hook V, Tseng CT, Larance M, Turville S, Gerwick WH, O'Donoghue AJ, Payne RJ. J Med Chem. 2022 Feb 24;65(4):2956-2970. doi: 10.1021/acs.jmedchem.1c01494. Epub 2021 Nov 3. PubMed
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. Raymonda MH, Ciesla JH, Monaghan M, Leach J, Asantewaa G, Smorodintsev-Schiller LA, Lutz MM 4th, Schafer XL, Takimoto T, Dewhurst S, Munger J, Harris IS. Virology. 2022 Jan;566:60-68. doi: 10.1016/j.virol.2021.11.008. Epub 2021 Nov 27. PubMed
A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. Valero J, Civit L, Dupont DM, Selnihhin D, Reinert LS, Idorn M, Israels BA, Bednarz AM, Bus C, Asbach B, Peterhoff D, Pedersen FS, Birkedal V, Wagner R, Paludan SR, Kjems J. Proc Natl Acad Sci U S A. 2021 Dec 14;118(50). pii: 2112942118. doi: 10.1073/pnas.2112942118. PubMed
Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2. Castiglione GM, Zhou L, Xu Z, Neiman Z, Hung CF, Duh EJ. PLoS Biol. 2021 Dec 21;19(12):e3001510. doi: 10.1371/journal.pbio.3001510. eCollection 2021 Dec. PubMed
Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection. Cui Q, Garcia G Jr, Zhang M, Wang C, Li H, Zhou T, Sun G, Arumugaswami V, Shi Y. iScience. 2022 Jan 21;25(1):103684. doi: 10.1016/j.isci.2021.103684. Epub 2021 Dec 24. PubMed
Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. Kim HK, Cho J, Kim E, Kim J, Yang JS, Kim KC, Lee JY, Shin Y, Palomera LF, Park J, Baek SH, Bae HG, Cho Y, Han J, Sul JH, Lee J, Park JH, Cho YW, Lee W, Jo DG. J Extracell Vesicles. 2022 Jan;11(1):e12179. doi: 10.1002/jev2.12179. PubMed
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Balachandran H, Phetsouphanh C, Agapiou D, Adhikari A, Rodrigo C, Hammoud M, Shrestha LB, Keoshkerian E, Gupta M, Turville S, Christ D, King C, Sasson SC, Bartlett A, Grubor-Bauk B, Rawlinson W, Aggarwal A, Stella AO, Klemm V, Mina MM, Post JJ, Hudson B, Gilroy N, Konecny P, Ahlenstiel G, Dwyer DE, Sorrell TC, Kelleher A, Tedla N, Lloyd AR, Martinello M, Bull RA. Cell Rep. 2022 Feb 8;38(6):110345. doi: 10.1016/j.celrep.2022.110345. Epub 2022 Jan 19. PubMed
Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2. Liu J, Lu F, Chen Y, Plow E, Qin J. J Biol Chem. 2022 Mar;298(3):101710. doi: 10.1016/j.jbc.2022.101710. Epub 2022 Feb 10. PubMed
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. Clark NM, Janaka SK, Hartman W, Stramer S, Goodhue E, Weiss J, Evans DT, Connor JP. PLoS One. 2022 Mar 8;17(3):e0257930. doi: 10.1371/journal.pone.0257930. eCollection 2022. PubMed
Construction of SARS-CoV-2 spike-pseudotyped retroviral vector inducing syncytia formation. Lee SY, Kim DW, Jung YT. Virus Genes. 2022 Jun;58(3):172-179. doi: 10.1007/s11262-022-01890-z. Epub 2022 Mar 23. PubMed
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Peng L, Hu Y, Mankowski MC, Ren P, Chen RE, Wei J, Zhao M, Li T, Tripler T, Ye L, Chow RD, Fang Z, Wu C, Dong MB, Cook M, Wang G, Clark P, Nelson B, Klein D, Sutton R, Diamond MS, Wilen CB, Xiong Y, Chen S. Nat Commun. 2022 Mar 28;13(1):1638. doi: 10.1038/s41467-022-29288-3. PubMed Associated Plasmids HH02-LP Clone 2 heavy chain HH06-LP Clone 6 heavy chain HH13 Clone 13 heavy chain HH13A Clone 13A heavy chain HK02-LP Clone 2 light chain More ...
Variable susceptibility of intestinal organoid-derived monolayers to SARS-CoV-2 infection. Jang KK, Kaczmarek ME, Dallari S, Chen YH, Tada T, Axelrad J, Landau NR, Stapleford KA, Cadwell K. PLoS Biol. 2022 Mar 31;20(3):e3001592. doi: 10.1371/journal.pbio.3001592. eCollection 2022 Mar. PubMed
Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction. Ahamad S, Ali H, Secco I, Giacca M, Gupta D. Front Genet. 2022 Mar 25;13:866474. doi: 10.3389/fgene.2022.866474. eCollection 2022. PubMed
Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. Lee RK, Li TN, Chang SY, Chao TL, Kuo CH, Pan MY, Chiou YT, Liao KJ, Yang Y, Wu YH, Huang CH, Juan HF, Hsieh HP, Wang LH. Int J Mol Sci. 2022 Apr 6;23(7):4050. doi: 10.3390/ijms23074050. PubMed
Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections. Rosendal E, Mihai IS, Becker M, Das D, Frangsmyr L, Persson BD, Rankin GD, Groning R, Trygg J, Forsell M, Ankarklev J, Blomberg A, Henriksson J, Overby AK, Lenman A. mBio. 2022 Jun 28;13(3):e0089222. doi: 10.1128/mbio.00892-22. Epub 2022 May 9. PubMed
Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Aggarwal A, Stella AO, Walker G, Akerman A, Esneau C, Milogiannakis V, Burnett DL, McAllery S, Silva MR, Lu Y, Foster CSP, Brilot F, Pillay A, Van Hal S, Mathivanan V, Fichter C, Kindinger A, Hoppe AC, Munier ML, Amatayakul-Chantler S, Roth N, Coppola G, Symonds GP, Schofield P, Jackson J, Lenthall H, Henry JY, Mazigi O, Jack HM, Davenport MP, Darley DR, Matthews GV, Khoury DS, Cromer D, Goodnow CC, Christ D, Robosa R, Starck DJ, Bartlett NW, Rawlinson WD, Kelleher AD, Turville SG. Nat Microbiol. 2022 Jun;7(6):896-908. doi: 10.1038/s41564-022-01135-7. Epub 2022 May 30. PubMed
The human EF1a promoter does not provide expression of the transgene in mice. Battulin N, Korablev A, Ryzhkova A, Smirnov A, Kabirova E, Khabarova A, Lagunov T, Serova I, Serov O. Transgenic Res. 2022 Oct;31(4-5):525-535. doi: 10.1007/s11248-022-00319-5. Epub 2022 Aug 12. PubMed
SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. Mannar D, Saville JW, Sun Z, Zhu X, Marti MM, Srivastava SS, Berezuk AM, Zhou S, Tuttle KS, Sobolewski MD, Kim A, Treat BR, Da Silva Castanha PM, Jacobs JL, Barratt-Boyes SM, Mellors JW, Dimitrov DS, Li W, Subramaniam S. Nat Commun. 2022 Aug 18;13(1):4696. doi: 10.1038/s41467-022-32262-8. PubMed
Metalloprotease-Dependent S2'-Activation Promotes Cell-Cell Fusion and Syncytiation of SARS-CoV-2. Harte JV, Wakerlin SL, Lindsay AJ, McCarthy JV, Coleman-Vaughan C. Viruses. 2022 Sep 21;14(10):2094. doi: 10.3390/v14102094. PubMed
Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. Bednash JS, Johns F, Farkas D, Elhance A, Adair J, Cress K, Yount JS, Kenney AD, Londino JD, Mallampalli RK. Am J Respir Cell Mol Biol. 2023 May;68(5):566-576. doi: 10.1165/rcmb.2022-0331OC. PubMed
Identification of Human Host Substrates of the SARS-CoV-2 M(pro) and PL(pro) Using Subtiligase N-Terminomics. Luo SY, Moussa EW, Lopez-Orozco J, Felix-Lopez A, Ishida R, Fayad N, Gomez-Cardona E, Wang H, Wilson JA, Kumar A, Hobman TC, Julien O. ACS Infect Dis. 2023 Apr 14;9(4):749-761. doi: 10.1021/acsinfecdis.2c00458. Epub 2023 Apr 3. PubMed
Identification of small molecules capable of enhancing viral membrane fusion. Garcia-Murria MJ, Gadea-Salom L, Moreno S, Rius-Salvador M, Zaragoza O, Brun A, Mingarro I, Martinez-Gil L. Virol J. 2023 May 24;20(1):99. doi: 10.1186/s12985-023-02068-1. PubMed
Correlating the differences in the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human ACE2 receptor. Mahalingam G, Arjunan P, Periyasami Y, Dhyani AK, Devaraju N, Rajendiran V, Christopher AC, Kt RD, Dhanasingh I, Thangavel S, Murugesan M, Moorthy M, Srivastava A, Marepally S. Sci Rep. 2023 May 30;13(1):8743. doi: 10.1038/s41598-023-35070-2. PubMed
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. Baggen J, Jacquemyn M, Persoons L, Vanstreels E, Pye VE, Wrobel AG, Calvaresi V, Martin SR, Roustan C, Cronin NB, Reading E, Thibaut HJ, Vercruysse T, Maes P, De Smet F, Yee A, Nivitchanyong T, Roell M, Franco-Hernandez N, Rhinn H, Mamchak AA, Ah Young-Chapon M, Brown E, Cherepanov P, Daelemans D. Cell. 2023 Aug 3;186(16):3427-3442.e22. doi: 10.1016/j.cell.2023.06.005. Epub 2023 Jul 7. PubMed

If you have published an article using this material, please email us at to have your article added to this page.